ClinicalTrials.gg
CompletedNCT03385369Updated Apr 16, 2019

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

A Phase 1 interventional study of MEDI0382 and Placebo in Safety and Healthy Subjects, sponsored by MedImmune LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2018, 8 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a phase I, randomized, blinded study to evaluate the safety and pharmacokinetics of MEDI0382 following single dose administration to overweight/obese subjects of Japanese or Chinese descent

Read the detailed description

This is a phase I, randomized, blinded study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of MEDI0382 following single dose administration to overweight/obese but otherwise healthy adult male and female subjects of Japanese or Chinese descent

02

Conditions studied

  • Safety
  • Healthy Subjects

Keywords

  • MEDI0382
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Immunogenicity
03

In context

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted after MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following criteria:

  1. Healthy subjects age 18 to 65 years inclusive at the time of consent.
  2. Written and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the USA), obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
  3. Female subjects of must have a negative serum or urine pregnancy test at screening and randomization, and must not be lactating.
  4. Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of from screening and must agree to continue using such precautions through to the end of the study. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
  5. Subject has a body weight ≥ 50 kg (110 lbs) and a ≥ 23 and ≤ 40 kg/m2 inclusive.
  6. Venous access suitable for multiple cannulations.

    Part A only:

  7. Subject is a native of Japan or a Japanese American; defined as having both parents and four grandparents who are Japanese. This includes second and third generation subjects of Japanese descent whose parents or grandparents are living in a country other than Japan.

Part B only:

  1. Subject is a native of China or a Chinese American; defined as having both parents and four grandparents who are Chinese. This includes second and third generation subjects of Chinese descent whose parents or grandparents are living in a country other than China.

____________________________________________________________

Exclusion criteria

Exclusion Criteria:

Any of the following would exclude the subject from participation in the study:

  1. Any condition that, in the opinion of the investigator, would interfere with evaluation of the product or interpretation of subject safety or study results. Specific examples are:

    1. Past history of acute or chronic pancreatitis, or pancreatic amylase or lipase greater than twice the (ULN) at screening.
    2. Past history of gastroparesis requiring treatment.
    3. Past history of surgery affecting the upper GI tract likely to affect the interpretation of safety and tolerability data.
    4. History of cholelithiasis leading to episodes of acute cholecystitis not treated by cholecystectomy, or known biliary disease.
    5. History of or family history of multiple endocrine neoplasia type 2; or serum calcitonin suggestive of thyroid C-cell hyperplasia (calcitonin level > 50 ng/L); or medullary thyroid carcinoma at screening.
    6. Past history of cardiac rhythm disturbance (eg, permanent or paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, paroxysmal ventricular tachycardia, presence of an implantable pacemaker device or cardioverter/defibrillator).
    7. History of treated or symptomatic cardiac failure.
    8. Impaired renal function, defined as estimated \< 60 mL/minute/1.73 m2 at screening.
  2. History of previous myocardial infarction or cerebrovascular accident (eg, stroke).
  3. History or presence of GI, renal, or hepatic disease (with the exception of Gilbert's syndrome), or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  4. History of cancer, with the exception of non-melanoma skin cancer.
  5. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to dosing.
  6. Positive surface antigen or virus antibody serology at screening.
  7. Positive test at screening or use of antiretroviral medications as determined by medical history or subject's verbal report.
  8. Any of the following based on screening blood tests:

    1. (AST) ≥ 1.5 × ULN.
    2. Alanine aminotransferase (ALT) ≥ 1.5 × ULN.
    3. Total ≥ 1.5 × ULN.
    4. below 12 g/dL.
    5. Neutrophils \< 1.5 × 10\^9/L.
    6. Thyroid stimulating hormone level above the normal range.
  9. Use of any of the following medicinal products:

    1. Concurrent or previous use of a GLP-1 receptor agonist.
    2. Current or previous use of systemic within the past 28 days prior to screening.
    3. Use of any licensed medicinal products, or herbal preparations for control of body weight or appetite, is prohibited from one week prior to Day -1 through Day 3.
  10. Abnormal vital signs after 10 minutes of supine rest, defined as any of the following:

    1. Systolic BP \< 90 mmHg or ≥ 140 mmHg.
    2. Diastolic BP \< 50 mmHg or ≥ 90 mmHg.
    3. Heart rate \< 45 or > 85 beats per minute.
  11. Any clinically important abnormalities in rhythm, conduction (eg, Wolff-Parkinson-White syndrome, sick-sinus syndrome), or morphology of the resting 12-lead , or any abnormalities in the ECG that, in the opinion of the investigator, may interfere with the interpretation of changes in the , including abnormal T-wave morphology, or left ventricular hypertrophy.
  12. Prolonged QTc using the Fridericia formula (QTcF) > 450 milliseconds, or shortened QTcF \< 340 milliseconds based on 12-lead ECG, or family history of long QT syndrome.
  13. PR (PQ) interval shortening \< 120 milliseconds (PR \< 120 but > 110 milliseconds is acceptable if there is no evidence of ventricular pre excitation).
  14. PR (PQ) interval prolongation (> 240 milliseconds), intermittent second degree block (Wenckebach block while asleep is not exclusive) or third degree block, or atrioventricular dissociation.
  15. Complete or intermittent complete bundle branch block, incomplete bundle branch block,or intraventricular conduction delay with QRS > 110 milliseconds. Subjects with QRS > 110 but \< 115 milliseconds are acceptable if there is no evidence of ventricular hypertrophy.
  16. Known or suspected history of drug abuse within the past 3 years as judged by the investigator.
  17. History of alcohol abuse or excessive intake of alcohol within the past 3 years as judged by the investigator.
  18. Positive screen for drugs of abuse or positive breath test for alcohol at screening. Subjects who use benzodiazepines for chronic anxiety or sleep disorders may be permitted to enter the study.
  19. History of severe allergy/ or ongoing clinically important allergy/hypersensitivity as judged by the investigator.
  20. Whole blood or red blood cell donation, or any blood loss > 500 mL within 2 months prior to screening.
  21. Receipt of another new chemical entity (defined as a compound that has not been approved for marketing), or participation in any other clinical study that included drug treatment within at least 30 days or 5 half-lives of the administration of investigational product in this study (whichever is longer). The period of exclusion will end 30 days or 5 half-lives of investigational product after the final dose, whichever is longest. Subjects consented and screened, but not randomized into this study or a previous study, will not be excluded.
  22. Psychiatric illness such that subjects have been committed to an institution by way of official or judicial order.
  23. The subject is an employee, or close relative of an employee, of AstraZeneca, MedImmune, the CRO, or the study site, regardless of the employee's role.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Placebo comparator
    Placebo Japanese Descent

    Participants of Japanese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.

    Drug: Placebo

  • Experimental
    MEDI0382 50 mcg Japanese Descent

    Participants of Japanese descent will receive a single subcutaneous dose of 50 mcg MEDI0382.

    Drug: MEDI0382

  • Experimental
    MEDI0382 100 mcg Japanese Descent

    Participants of Japanese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.

    Drug: MEDI0382

  • Experimental
    MEDI0382 150 mcg Japanese Descent

    Participants of Japanese descent will receive a single subcutaneous dose of 150 mcg MEDI0382.

    Drug: MEDI0382

  • Experimental
    Placebo Chinese Descent

    Participants of Chinese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.

    Drug: Placebo

  • Experimental
    MEDI0382 100 mcg Chinese Descent

    Participants of Chinese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.

    Drug: MEDI0382

Interventions

  • Single dose of MEDI0382

  • DrugPlacebo

    Single dose of placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug and up to Day 29.

    Time frame: Day 1 through Day 29

  2. Number of Participants With Treatment Emergent Adverse Events of Special Interest (AESIs)

    An AESI (serious or non-serious) was one of scientific and medical interest specific to understanding of study drug and may have required close monitoring and rapid communication by investigator to the sponsor.

    Time frame: Day 1 through Day 29

  3. Number of Participants With Abnormal Electrocardiogram (ECG) Reported as TEAEs

    Number of participants with TEAEs related to clinically significant ECG abnormalities are reported.

    Time frame: Day 1 through Day 29

  4. Number of Participants With Vital Signs Abnormalities Reported as TEAEs

    Number of participants with TEAEs related to vital sign abnormalities are reported.

    Time frame: Day 1 through Day 29

  5. Number of Participants With Abnormal Laboratory parameters Reported as TEAEs

    Number of participants with TEAEs related to clinically significant abnormal laboratory parameter are reported.

    Time frame: Day 1 through Day 29

Secondary outcomes

  1. Number of Participants With Postive Anti-Drug Antibodies (ADA) Titer to MEDI0382

    The number of participants with positive serum antibodies to MEDI0382 are reported.

    Time frame: Baseline (Day-1), Day 8, and Day 29

  2. Maximum Observed Plasma Concentration (Cmax) of MEDI0382

    Time frame: Pre dose; and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post dose

  3. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI0382

    Time frame: Pre dose; and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post dose

  4. Area Under the Concentration-time Curve From Time Zero to Last Time of Quantifiable Concentration (AUC0 last) of MEDI0382

    Time frame: Pre dose; and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post dose

  5. Time to Maximum Observed Plasma Concentration (tmax) of MEDI0382

    Time frame: Pre dose; and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post dose

  6. Apparent Terminal Elimination Half-life (t1/2) of MEDI0382

    Time frame: Pre dose; and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post dose

  7. Apparent Clearance (CL/F) of MEDI0382

    Time frame: Pre dose; and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post dose

07

Study locations

1 site
  • Research Site
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Apr 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2017
First posted
Dec 28, 2017
StartActual
Jan 5, 2018
Primary completionActual
Apr 12, 2018
CompletionActual
Apr 12, 2018
Last update
Apr 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03385369
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Dec 28, 2017
Start date
Jan 5, 2018
Primary completion
Apr 12, 2018
Completion
Apr 12, 2018
Last update
Apr 16, 2019

Study contacts

Peter J Winkle, MD, FACP, FACG, CPI
principal investigator · Anaheim Clinical Trials LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cotadutide

Start the discussion